Reservoirs for HIV infection and their persistence in the face of undetectable viral load

AIDS Patient Care and STDs

Volumn 15, Issue 10, 2001, Pages 511-518

  Sonza, S ^a   Crowe, S M ^a  

^a MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; INTERLEUKIN 2;

BRAIN; ERADICATION THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MACROPHAGE; PROTEIN EXPRESSION; REVIEW; VIRUS LOAD; VIRUS REPLICATION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BRAIN; HIV INFECTIONS; HIV-1; HUMANS; MACROPHAGES; VIRAL LOAD; VIRUS LATENCY; VIRUS REPLICATION;

EID: 0034763958     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/108729101753205676     Document Type: Review

References (85)

1. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
2. Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
3. Decrease of HIV-1 RNA levels in lymphoid tissue and peripheral blood during treatment with ritonavir, lamivudine and zidovudine
4. Decay characteristics of HIV-1 infected compartments during combination therapy
5. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
6. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
7. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy
8. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy
9. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
10. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection
11. Toward HIV eradication or remission: The tasks ahead
12. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged antiretroviral therapy
13. Viral reservoirs and ongoing virus replication in patients on HAART: Implications for clinical management
14. Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle
15. Ib phase of the cell cycle is required for completion of human immunodeficiency virus type 1 reverse transcription in T cells
16. HIV-1 replication is controlled at the level of T cell activation and proviral integration
17. A new latent HIV reservoir
18. Generation of HIV latency during thymopoiesis
19. Characterization of chemokine receptor utilization of viruses in the latent reservoir for human immunodeficiency virus type 1
20. Biphasic decay of latently infected CD4+ T cells in acute human immunodeficiency virus type 1 infection
21. Early establishment of a pool of latently infected, resting CD4+ T cells during primary HIV-1 infection
22. Viral load and burden modification following early antiretroviral therapy of primary HIV-1 infection
23. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses
24. Both memory and CD45RA+/CD62L+ naïve CD4+ T cells are infected in human immunodeficiency virus type 1-infected individuals
25. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy
26. Persistence of human immunodeficiency virus in semen after adding indinavir to combination antiretroviral therapy
27. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy
28. Cervical and prostate primary epithelial cells are not productively infected but sequester human immunodeficiency virus type 1
29. Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy
30. Persistence of infectious HIV on follicular dendritic cells
31. Life in the fast lane in a slow infection: Implications for vaccine development of events in early infection
32. Persistence of HIV-1 transcription in peripheral blood mononuclear cells in patients receiving potent antiretroviral therapy
33. Persistence of episomal HIV-1 infection intermediates in patients on highly active antiretroviral therapy
34. A quantitative assay for HIV DNA integration in vivo
35. Human immunodeficiency virus type 1-infected persons with residual disease and virus reservoirs on suppressive highly active antiretroviral therapy can be stratified in relevant virologic and immunologic subgroups
36. Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy
37. Absence of genetic diversity reduction in the HIV-1 integrated provirus LTR sequence population during successful combination therapy
38. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression
39. Pre-HAART HIV burden approximates post-HAART viral levels following interruption of therapy in patients with sustained viral suppression
40. Rapid activation of lymph nodes and mononuclear cell HIV expression upon interrupting highly active antiretroviral therapy in patients after prolonged viral suppression
41. Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active antiretroviral therapy
42. Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy
43. HIV infection in macrophage: Role of long-lived cells and related therapeutical strategies
44. Quantitative immunocytofluorographic analysis of CD4 surface antigen expression and HIV infection of human peripheral blood monocyte/macrophages
45. Comparative assessment of antiretrovirals in human monocyte-macrophages and lymphoid cell lines acutely and chronically infected with the human immunodeficiency virus
46. In vitro activity of inhibitors of late stages of replication of HIV in chronically infected macrophages
47. Relative potency of protease inhibitors in monocyte/macrophages acutely and chronically infected with human immunodeficiency virus
48. In vitro blood brain barrier permeability of nevirapine compared to other HIV antiretroviral agents
49. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors
50. Cells of the monocyte-macrophage lineage and pathogenesis of HIV-1 infection
51. HIV-1 can be recovered from a variety of cells including peripheral blood monocytes of patients receiving highly active antiretroviral therapy
52. Monocytes harbor replication-competent, non-latent HIV-1 in patients on highly active antiretroviral therapy
53. Detection of infectious HIV in circulating monocytes from patients on prolonged highly active antiretroviral therapy
54. HIV-1 genotypes in peripheral blood monocytes
55. Dynamics of viral load in plasma and HIV DNA in lymphocytes during highly active antiretroviral therapy (HAART): High viral burden in macrophages after 1 year of treatment
56. Macrophages are the principal reservoir and sustain high virus loads in rhesus macaques after depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections in humans
57. Macrophages as a source of HIV during opportunistic infections
58. Co-infection with opportunistic pathogens promotes human immunodeficiency virus type 1 infection in macrophages
59. Infection of HIV-1 transgenic mice with Mycobacterium avium induces the expression of infectious virus selectively from a Mac-1-positive host cell population
60. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes
61. Modulation of P-glycoprotein function in human lymphocytes and Caco2 cell monolayers by HIV-1 protease inhibitors
62. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly antiretroviral therapy
63. Kinetics of productive and latent HIV infection in lymphatic tissue and peripheral blood during triple-drug combination therapy with or without additional interleukin-2
64. + T cell demographics and dynamics in lymphatic tissue
65. Residual human immunodeficiency virus (HIV) type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years
66. Constant mean viral copy number per infected cell in tissues regardless of high, low or undetectable plasma HIV RNA
67. Compartments and reservoirs of HIV infection in vivo
68. Nonlymphoid reservoirs of HIV replication in children with chronic-progressive disease
69. Independent HIV replication in paired CSF and blood viral isolates during antiretroviral therapy
70. Comparison of human immunodeficiency virus type 1 RNA sequence heterogeneity in cerebrospinal fluid and plasma
71. Despite high concordance, distinct mutational and phenotypic drug resistance profiles in human immunodeficiency virus type 1 RNA are observed in gastrointestinal mucosal biopsy specimens and peripheral blood mononuclear cells compared with plasma
72. Evidence for independent development of resistance to HIV-1 reverse transcriptase inhibitors in the cerebrospinal fluid
73. HIV-1 selection by epidermal dendritic cells during transmission across human skin
74. Molecular evidence for drug-induced compartmentalization of HIV-1 quasispecies in a patient with periodic changes to HAART
75. Evidence for late stage compartmentalization of HIV-1 resistance mutations between lymph node and peripheral blood mononuclear cells
76. Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples
77. Mononuclear phagocytes egress from an in vitro model of the vascular wall by migrating across endothelium in the basal to apical direction: Role of the intercellular adhesion molecule 1 and the CD11/CD18 integrins
78. Infection of gastrointestinal tract macrophages by HIV-1
79. Mononuclear phagocyte heterogeneity and the blood-brain barrier: A model for HIV-1 neuropathogenesis
80. + T cells using a combination of cytokines
81. New trends in antiretroviral therapy for HIV infection
82. The effects of interleukin-2 therapy on the viral reservoir in HIV+ patients
83. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy
84. Immune control of HIV-1 after early treatment of acute infection
85. Boosting immunity to HIVCan the virus help?